Clovis Oncology Inc. (NASDAQ:CLVS) was down 6% during trading on Tuesday . The stock traded as low as $14.14 and last traded at $14.14, with a volume of 313,404 shares trading hands. The stock had previously closed at $15.04.

Several equities research analysts recently commented on CLVS shares. Piper Jaffray Cos. reiterated a “hold” rating and set a $18.00 target price on shares of Clovis Oncology in a report on Tuesday, April 5th. Vetr upgraded Clovis Oncology from a “buy” rating to a “strong-buy” rating and set a $17.71 target price on the stock in a report on Thursday, June 9th. Credit Suisse Group AG reiterated a “hold” rating on shares of Clovis Oncology in a report on Tuesday, July 12th. Mizuho dropped their target price on Clovis Oncology from $21.00 to $15.00 and set a “neutral” rating on the stock in a report on Monday, April 11th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $30.00 target price on shares of Clovis Oncology in a report on Thursday, June 30th. Seven equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $29.25.

The firm’s 50 day moving average price is $14.01 and its 200 day moving average price is $16.59. The stock’s market capitalization is $563.11 million.

Clovis Oncology (NASDAQ:CLVS) last issued its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.17) EPS for the quarter, beating analysts’ consensus estimates of ($2.39) by $0.22. Clovis Oncology’s revenue was up NaN% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.86) earnings per share. Analysts predict that Clovis Oncology Inc. will post ($8.00) earnings per share for the current fiscal year.

A number of hedge funds and institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System increased its position in shares of Clovis Oncology by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 51,609 shares of the biopharmaceutical company’s stock worth $1,806,000 after buying an additional 889 shares during the period. Rhumbline Advisers increased its position in shares of Clovis Oncology by 6.6% in the fourth quarter. Rhumbline Advisers now owns 30,237 shares of the biopharmaceutical company’s stock worth $1,058,000 after buying an additional 1,880 shares during the period. Finally, Trexquant Investment LP purchased a new position in shares of Clovis Oncology during the fourth quarter worth approximately $3,170,000.

Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.